| Ms Stephanie Drewry Baynton, MSN | |
|
1970 Roanoke Blvd, Clinic 1 11ac, Salem, VA 24153-6404 | |
| (540) 982-2463 | |
| (540) 224-1904 |
| Full Name | Ms Stephanie Drewry Baynton |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Medical-surgical |
| Location | 1970 Roanoke Blvd, Salem, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285697052 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SM0705X | Clinical Nurse Specialist - Medical-surgical | 0015000585 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Stephanie Drewry Baynton, MSN 1970 Roanoke Blvd, Clinic 1 11ac, Salem, VA 24153-6404 Ph: (540) 982-2463 | Ms Stephanie Drewry Baynton, MSN 1970 Roanoke Blvd, Clinic 1 11ac, Salem, VA 24153-6404 Ph: (540) 982-2463 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.
At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.
PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.
One of the world's leading researchers in dementia, Professor John Hodges, has taken up an appointment with the University of New South Wales (UNSW) and the Prince of Wales Medical Research Institute (POWMRI).
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19).
› Verified 2 days ago